Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 18, 2008, Pages 5118-5122

  Stec, Markian M ^a   Bo, Yunxin ^a   Chakrabarti, Partha P ^a   Liao, Lillian ^a   Ncube, Mqhele ^a   Tamayo, Nuria ^a   Tamir, Rami ^a   Gavva, Narender R ^a   Treanor, James J S ^a   Norman, Mark H ^a  

^a AMGEN INC   (United States)

Author keywords

AMG 517; Ion channel; Transient receptor potential; TRPV1; Vanilloid receptor; VR1

Indexed keywords

AMG 517; CAPSAICIN; PYRIMIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NONHUMAN; RAT;

ANIMALS; BENZOTHIAZOLES; COMBINATORIAL CHEMISTRY TECHNIQUES; MOLECULAR STRUCTURE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TRPV CATION CHANNELS;

EID: 51349101083     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.112     Document Type: Article

References (27)

1. Szallasi A., and Blumberg P.M. Pharmacol. Rev. 51 (1999) 159
2. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. Nature 389 (1997) 816
3. Tominaga M., Caterina M.J., Malmberg A.B., Rosen T.A., Gilbert H., Skinner K., Raumann B., Basbaum A.I., and Julius D. Neuron 21 (1998) 531
4. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., and Davis J.B. Br. J. Pharmacol. 129 (2000) 227
5. Ji R.-R., Samad T.A., Jin S.-X., Schmoll R., and Woolf C.J. Neuron 36 (2002) 57
6. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., Koltzenburg M., Basbaum A.I., and Julius D. Science 288 (2000) 306
7. Davis J.B., Gray J., Gunthorpe M.J., Hatcher J.P., Davey P.T., Overend P., Harries M.H., Latcham J., Clapham C., Atkinson K., Hughes S.A., Rance K., Grau E., Harper A.J., Pugh P.L., Rogers D.C., Bingham S., Randall A., and Sheardown S.A. Nature 405 (2000) 183
8. Gavva N.R., Tamir R., Qu Y., Klionsky L., Zhang T.J., Immke D., Wang J., Zhu D., Vanderah T.W., Porreca F., Doherty E.M., Norman M.H., Wild K.D., Bannon A.W., Louis J.-C., and Treanor J.J.S. J. Pharmacol. Exp. Ther. 313 (2005) 474
9. Gomtsyan A., Bayburt E.K., Schmidt R.G., Zheng G.Z., Perner R.J., Didomenico S., Koenig J.R., Turner S., Jinkerson T., Drizin I., Hannick S.M., Macri B.S., McDonald H.A., Honore P., Wismer C.T., Marsh K.C., Wetter J., Stewart K.D., Oie T., Jarvis M.F., Surowy C.S., Faltynek C.R., and Lee C.-H. J. Med. Chem. 48 (2005) 744
10. Honore P., Wismer C.T., Mikusa J., Zhu C.Z., Zhong C., Gauvin D.M., Gomtsyan A., El Kouhen R., Lee C.-H., Marsh K., Sullivan J.P., Faltynek C.R., and Jarvis M.F. J. Pharmacol. Exp. Ther. 314 (2005) 410
11. Pomonis J.D., Harrison J.E., Mark L., Bristol D.R., Valenzano K.J., and Walker K. J. Pharmacol. Exp. Ther. 306 (2003) 387
12. Rami H.K., and Gunthorpe M.J. Drug Discov. Today 1 (2004) 97
13. For a discussion of AMG 517 and examples of compounds that were selective toward capsaicin or acid activation, see:. Doherty E.M., Fotsch C., Bannon A.W., Bo Y., Chen N., Dominguez C., Falsey J., Gavva N.R., Katon J., Nixey T., Ognyanov V.I., Pettus L., Rzasa R.M., Stec M., Surapaneni S., Tamir R., Zhu J., Treanor J.J.S., and Norman M.H. J. Med. Chem. 50 (2007) 3515
14. Wang H.-L., Katon J., Balan C., Bannon A.W., Bernard C., Doherty E.M., Dominguez C., Gavva N.R., Gore V., Ma V., Nishimura N., Surapaneni S., Tang P., Tamir R., Thiel O., Treanor J.J.S., and Norman M.H. J. Med. Chem. 50 (2007) 3528
15. Wang X., Chakrabarti P.P., Ognyanov V.I., Pettus L.H., Tamir R., Tan H., Tang P., Treanor J.J.S., Gavva N.R., and Norman M.H. Bioorg. Med. Chem. Lett. 17 (2007) 6539
16. Doherty E.M., Fotsch C., Bo Y., Chakrabarti P.P., Chen N., Gavva N., Han N., Kelly M.G., Kincaid J., Klionsky L., Liu Q., Ognyanov V.I., Tamir R., Wang X., Zhu J., Norman M.H., and Treanor J.J.S. J. Med. Chem. 48 (2005) 71
17. Norman M.H., Zhu J., Fotsch C., Bo Y., Chen N., Chakrabarti P., Doherty E.M., Gavva N.R., Nishimura N., Nixey T., Ognyanov V.I., Rzasa R.M., Stec M., Surapaneni S., Tamir R., Viswanadhan V.N., and Treanor J.J.S. J. Med. Chem. 50 (2007) 3497
18. 0-∞ = 5400 ng h/mL.
19. Boisnard S., Carbonnelle A.-C., and Zhu J. Org. Lett. 3 (2001) 2061
20. Hewawasam P., and Meanwell N.A. Tetrahedron Lett. 35 (1994) 7303
21. Coste J., Frerot E., Jouin P., and Castro B. Tetrahedron Lett. 32 (1991) 1967
22. Tamayo N., Liao H., Stec M.M., Wang X., Chakrabarti P., Retz D., Doherty E.M., Surapaneni S., Tamir R., Bannon A.W., Gavva N., and Norman M.H. J. Med. Chem. 51 (2008) 5744
23. Tan H., Semin D., Wacker M., and Cheetham J. JALA 10 (2005) 364
24. Compounds dosed intravenously at 1 mg/kg in DMSO into fed male Sprague-Dawley rats with sampling time up to 6 h. n = 2 animals per study. Interanimal variability was less than or equal to 30%.
25. 2 for 1 or 2 h. The reaction was stopped by the addition of acetonitrile or methanol. After vortexing and centrifugation, the supernatant was analyzed by LC/MS.
26. ACD/pKa DB, Version 8.07; Advanced Chemistry Development Inc., Toronto, Ontario, Canada, 2004.
27. Compounds dosed orally at 5 mg/kg as a suspension in 5% Tween 80/Oraplus into fasted male Sprague-Dawley rats with sampling time up to 8 h. n = 2 animals per study. Interanimal variability was less than or equal to 30%.